Our article Nanomedicines – what are they? (DTB 2011; 49: 58–60) reported that medicines containing nanoparticles available in the EU include oral suspensions of aprepitant (Emend) and sirolimus (Rapamune). The source of this information was a European Medicines Agency document, stating that medicinal products containing nanoparticles in the form of “suspensions (i.e. Rapamune, Emend) have already been granted Marketing Authorisations within the Community under the existing regulatory framework”.1 We have since learned that there are no oral suspension formulations of these drugs marketed in the EU.